美股异动丨诺和诺德盘前跌11% CagriSema试验效果不及礼来的Zepbound

Group 1 - The core point of the article is that Novo Nordisk's stock dropped 11% in pre-market trading following the release of data for CagriSema, indicating that its effectiveness was inferior to Eli Lilly's Zepbound [1] Group 2 - Novo Nordisk announced that the results from the trial of CagriSema were not as effective as those of Eli Lilly's Zepbound [1]